The downregulation of miR-181a/b has shown therapeutic benefits in neurodegenerative disorders, including RP caused by mutations in the Rhodopsin (Rho) and Phosphodiesterase 6β (Pde6β) genes [18, 36]. The gene discussed is PDE6B; the disease is retinitis pigmentosa 1.